Researchers at AAIC 2020 reported promising findings from preliminary studies of potential new MRI contrast agents for identifying early signs of neurodegeneration.
In one study, researchers performed a dose-ranging efficacy study of ADx-001, an amyloid-targeted liposomal macrocyclic gadolinium (Gd) contrast agent, for in vivo MRI of amyloid plaques in mice. They used a transgenic mouse model of early-onset Alzheimer’s disease, in which amyloid plaques develop from 6-7 months of age, and wide-type amyloid-negative controls.